Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02501629 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 177
- Enrollment target
NCT02501629 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 177 participants.
The verdict
NCT02501629, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 177 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the ability of reslizumab administered by subcutaneous injection to produce a corticosteroid-sparing effect in patients with oral corticosteroid (OCS)-dependent asthma and elevated blood eosinophils, without loss of asthma control.
Interventions
- DRUG Placebo
- DRUG Reslizumab
- DRUG Non-Oral Corticosteroid (non-OCS) Asthma Medication
- DRUG Oral Corticosteroid (OCS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2015-09-29 |
| Est. Completion | 2017-12-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02501629
The ClinicalTrials.gov registry entry for NCT02501629 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02501629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02501629 about?
NCT02501629 is a clinical study titled "An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils". The primary objective of the study is to determine the ability of reslizumab administered by subcutaneous injection to produce a corticosteroid-sparing effect in patients with oral corticosteroid (OCS)-dependent asthma and elevated blood eosinophils, without loss of asthma control.
What is the current status of trial NCT02501629?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 177 participants. The study started on 2015-09-29. Estimated completion is 2017-12-04.
What interventions are being tested in trial NCT02501629?
The interventions under investigation include: Placebo (DRUG), Reslizumab (DRUG), Non-Oral Corticosteroid (non-OCS) Asthma Medication (DRUG), Oral Corticosteroid (OCS) (DRUG).
Who is sponsoring clinical trial NCT02501629?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.